HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Jin Gu Lee Dae Joon Kim Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Park, I. K. Articles by Chung, K. Y. Search for Related Content PubMed PubMed Citation Articles by Park, I. K. Articles by Chung, K. Y. Related Collections Mediastinum

Eur J Cardiothorac Surg 2006;30:525-528
© 2006 Elsevier Science NL

Complete stable remission after extended transsternal thymectomy in myasthenia gravis

^a Department of Thoracic and Cardiovascular Surgery, Yonsei University College of Medicine, CPO Box 8044, Seoul 120-752, South Korea
^b Department of Thoracic and Cardiovascular Surgery, Jae Saeng Hospital, Bundang, South Korea

Received 3 April 2006; received in revised form 2 June 2006; accepted 6 June 2006.

^_* Corresponding author. Tel.: +82 2 2228 2140; fax: +82 2 393 6012. (Email: kychu{at}yumc.yonsei.ac.kr).

Objective: This study sought to determine the efficacy and prognostic factors of extended transsternal thymectomy as a treatment for myasthenia gravis (MG). Methods: Medical records of 147 patients who underwent extended transsternal thymectomy for MG from January 1991 to December 2002 were reviewed retrospectively. The complete stable remission (CSR) rate and prognostic factors for CSR were assessed in 106 female and 41 male patients. Results: The median age was 35 years (range 11–75 years). Ninety-eight patients had non-thymomatous MG and 49 patients had thymomatous MG. The median follow-up time was 89.7 months (range 12–167 months). Both non-thymomatous MG and thymomatous MG exhibited significant differences in population characteristics and CSR rates (29.6% vs 13.3% at 5 years, 45.2% vs 27.7% at 10 years, p = 0.022). Steroid therapy (hazard ratio: 0.234, p = 0.003) was a poor prognostic factor, while early onset (hazard ratio: 3.519, p = 0.048) was a good prognostic factor for CSR in non-thymomatous MG. In contrast, steroid therapy (hazard ratio: 0.061, p = 0.034) was poor prognostic factor for thymomatous MG. Conclusions: Extended transsternal thymectomy is a good treatment tool to achieve CSR in MG. Thymomatous MG and non-thymomatous MG were significantly different in patient characteristics and prognosis. Prognostic factors were steroid therapy and age of onset in non-thymomatous MG, and steroid therapy in thymomatous MG.

Key Words: Myasthenia gravis • Extended transsternal thymectomy • Complete stable remission

This article has been cited by other articles:

				J. R. SONETT and A. JARETZKI III Thymectomy for Nonthymomatous Myasthenia Gravis: A Critical Analysis Ann. N.Y. Acad. Sci., June 1, 2008; 1132(1): 315 - 328. [Abstract] [Full Text] [PDF]